Background Asthma is a chronic inflammatory disease characterized by reversible bronchial constriction, pulmonary inflammation and airway remodeling. Current standard therapies for asthma provide symptomatic control, but fail to target the underlying disease pathology. Furthermore, no therapeutic agent is effective in preventing airway remodeling. A substantial amount of evidence suggests that statins have anti-inflammatory properties and immunomodulatory activity. In this study, we investigated the effect of rosuvastatin on airway inflammation and its inhibitory mechanism in mucus hypersecretion in a murine model of chronic asthma. Methods BALB/c mice were sensitized and challenged by ovalbumin to induce asthma. The recruitment of inflammatory cells into bronchoalveolar lavage fluid （BALF） and the lung tissues were measured by Diff-Quik staining and hematoxylin and eosin （H＆E） staining. ELISA was used for measuring the levels of IL-4, IL-5, IL-13 and TNF-a in BALE Periodic acid-Schiff （PAS） staining was used for mucus secretion. Gamma-aminobutyric acid type A receptor （GABAAR） β2 expression was measured by means of immunohistochemistry, reverse transcription-polymerase chain reaction （RT-PCR） and Western blotting. Results Rosuvastatin reduced the number of total inflammatory cells, lymphocytes, macrophages, neutrophils, and eosinophils recruited into BALF, the levels of IL-4, IL-5, IL-13 and TNF-a in BALF, along with the histological mucus index （HMI） and GABAAR 132 expression. Changes occurred in a dose-dependent manner. Conclusions Based on its ability to reduce the inflammatory response and mucus hypersecretion by regulating GABAAR activity in a murine model of chronic asthma, rosuvastatin may be a useful therapeutic agent for treatment of asthma.
目的 评价无创双水平正压通气联合纳洛酮治疗慢性阻塞性肺疾病急性加重（AECOPD）并发肺性脑病（PE）的效果.方法 计算机检索Pubmed、ISI Web of knowledge、中国生物医学文献数据库、中国知网期刊数据库、万方资源数据库,收集国内外发表的关于BiPAP通气联合纳洛酮治疗AECOPD并发PE的相关文献,并按照纳入标准和排除标准筛选初步入选的随机对照实验（RCT）.进行质量评价后,提取有效数据并利用RevMan 5.2软件进行meta分析.结果 共纳入10篇RCT文献,包括697例患者（试验组353例,对照组343例）,系统评价结果表明：BiPAP联合纳洛酮治疗有助于提高AECOPD合并PE患者的PaO2[WMD =4.10,95％ CI （2.83,5.38）,P＜0.00001]、pH值[WMD =0.04,95％ CI （0.02,0.05）,P＜0.00001]及临床有效率[OR=3.58,95％ CI（2.22,5.76）,P＜0.00001],降低PaCO2[WMD=-5.78,95％CI（-6.87,4.69）,P＜0.00001]、再插管率[OR=0.19,95％ CI （0.11,0.35）,P＜0.00001].但不能有效降低死亡率[OR=0.38,95％ CI（0.11,1.34）,P=0.13].结论 BiPAP联合纳洛酮治疗AECOPD并发PE可以改善患者血气指标,提高临床疗效,降低再插管率,但不能有效降低死亡率.
